TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04497961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 1800 milligrams (mg) subcutaneous (SC) injection of daratumumab as follows: days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3-6; day 1 of cycles 7-36

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: EORTC QLQ-C30, EORTC QLQ-MY20, PRO-CTCAE)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The intervention, consisting of fully prepared whole foods plant based (WFPBD) meals and behavioral coaching provided by Daily Harvest. Patients receive self-selected WFPBD meals (lunch/dinner) for 12 weeks, along with guidance for snacks and breakfast. Behavioral counseling will be provided by health coaches and a research dietitian. The first 15 participants on each arm interested in this intervention will be enrolled on C13D1 or C25D1.
Study: NCT01942967

Intervention type: OTHER
Intervention: Echocardiography
Description: Measurement of:~* Left ventricular output (LVO).~* Right ventricular output (RVO).~* Assessment of the Mesenteric Artery Flow.

Intervention type: OTHER
Intervention: Near Infrared Spectroscopy Monitoring
Description: Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
Study: NCT03189134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescite
Description: Dilute fluorescite will be applied to cardiac tissue prior to imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio 100 Series System with Confocal Miniprobes
Description: Microscopy system will image cardiac tissue.
Study: NCT02799095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 4230
Description: Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 4230 + pembrolizumab
Description: IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Study: NCT01916889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RACY test
Study: NCT01520350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Adjunctive Aripiprazole
Description: low-dose 2-5mg/d for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT03241654

Intervention type: PROCEDURE
Intervention: flow trigger
Description: The flow trigger will be adjust during the pressure assist ventilation.
Study: NCT03568149

Intervention type: PROCEDURE
Intervention: assessment of pelvic vascular insufficiency signs
Description: Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree.

Intervention type: PROCEDURE
Intervention: assessment of pelvic vascular insufficiency signs
Description: Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree.
Study: NCT03232424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: * Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal or intensity modulated radiation therapy (IMRT)
Description: Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
Study: NCT02432560

Intervention type: DRUG
Intervention: Sirolimus
Description: Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.

Intervention type: DRUG
Intervention: Everolimus
Description: Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
Study: NCT02969343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Safety health information technology
Description: Patient safety technology toolkits on hospital care units
Study: NCT04339777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total body Irradiation
Description: 200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
Study: NCT01519245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
Study: NCT04339777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study: NCT03041987

Intervention type: OTHER
Intervention: Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Study: NCT01474083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment A: GK1-399 200 mg. Oral administration, twice per day.
Study: NCT04339777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Stem cell transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tacro)
Description: Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tacro)
Description: Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (Cytoxan)
Description: Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (Cytoxan)
Description: Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
Study: NCT03424733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plegridy
Description: Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plegridy
Description: Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol Pill
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol Pill
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Study: NCT05770973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany
Description: Compression dressing after ptosis surgery
Study: NCT02719509

Intervention type: PROCEDURE
Intervention: Cardiac Ultrasound
Study: NCT01474083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment B: GK1-399 800 mg. Oral administration, once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK1-399 (formerly TTP399)
Description: Treatment C: GK1-399 800 mg. Oral administration, twice per day.
Study: NCT02723955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab (GSK3359609)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU) plus carboplatin or cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobolimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Study: NCT04627285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: * Pharmaceutical form: Oral-solution~* Route of administration: Oral use~Subjects will receive lacosamide in a pre-specified sequence during the Treatment Period.
Study: NCT03647163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
Study: NCT01987986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: injectible intervention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: injectible intervention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: injectible intervention

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03901612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Continuous post operative regional analgesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 09%
Description: Continuous post operative regional analgesia
Study: NCT04680286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, intravenous bolus. Administered as the experimental arm.
Study: NCT02307019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program on specific prevention of health
Description: The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program on general prevention of health
Description: The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
Study: NCT03411213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diffuse optical tomography
Description: Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diffuse optical tomography
Description: Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
Study: NCT01670513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Low Strength
Description: 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 High Strength
Description: 8 weeks
Study: NCT01474083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo. Oral administration.
Study: NCT00939640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH/sodium-restricted diet (SRD)
Description: Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
Study: NCT04205981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
Study: NCT00886561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Description: Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV risk reduction intervention
Description: Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
Study: NCT03882112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601 40mg
Description: Single dosing of HIP1601 40mg, orally
Study: NCT03215264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 600-1200mg daily
Study: NCT03647163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT03215264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 600-1200mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: 600-1200mg daily
Study: NCT03647163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT03215264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 3-5mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 3-5mg weekly
Study: NCT03647163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab + nivolumab
Description: Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab + nivolumab
Description: Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg
Study: NCT02320435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: In general, patients will continue to receive 420 milligrams (mg) of pertuzumab administered as an intravenous infusion every 3 weeks following the guidance of the Parent protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: If trastuzumab intravenous infusions were given in combination with pertuzumab as part of the Parent study, patients will continue to receive treatment at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Study: NCT03215264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 3-5mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg daily
Study: NCT02320435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Combination Anti-Cancer Therapies
Description: If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Study: NCT03215264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: 160mg daily
Study: NCT02151006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA